AbbVie wagers more than $1B on Gilgamesh’s psychedelic drug
The asset deal thrusts AbbVie to the forefront of the psychedelic field, handing it a therapy that recently scored positive Phase 2 results in major depression.
Previous Post
Understanding Kidney Transplant and Recovery in Children
Next Post
Solriamfetol for Treatment of EDS in Patients With OSA
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago